Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

被引：0
|
作者：
Papageorgiou, Loula [1 ,2 ]
Fotiou, Despina [3 ]
Van Dreden, Patrick [4 ]
Garderet, Laurent [5 ,6 ]
Dimopoulos, Meletios A. [3 ,7 ]
Elalamy, Ismail [8 ]
Mohty, Mohamad [9 ,10 ,11 ]
Gerotziafas, Grigoris [12 ,13 ]
机构：
[1] Univ Pierre & Marie Curie UPMC, Paris Fac Med Pierre & Marie Curie, Inst Univ Cancerol IUC, Sorbonne Univ,Canc Biol & Therapeut,INSERM U938, Paris, France
[2] Tenon Univ Hosp, AP HP, Dept Haematol, Paris, France
[3] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece
[4] Stago, Clin Res, Gennevilliers, France
[5] Hop Pitie Salpetiere, AP HP, Serv Hematol, Paris, France
[6] Hop St Antoine, Ctr Rech St Antoine, Team Proliferat & Differentiat Stem Cells, Paris, France
[7] Univ Athens, Dept Clin Therapeut, Sch Med, Athens, Greece
[8] Paris 6 Univ, AP HP, Paris 20, France
[9] St Antoine Hosp, Dept Haematol, INSERM UMR 938, Paris, France
[10] St Antoine Hosp, EBMT Paris Study Off CEREST TC, INSERM UMR 938, Paris, France
[11] Univ Paris 06, Paris, France
[12] Sorbonne Univ, Inst Univ Cancerol, INSERM, Canc Haemostasis & Angiogenesis Res Grp, Paris, France
[13] Hop Tenon, AP HP, Thrombosis Ctr, Serv Hematol Biol, Paris, France
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126954
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1913
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study
    Gerotziafas, Grigorios T.
    Fotiou, Despina
    Sergentanis, Theodoros N.
    Papageorgiou, Loula
    Fareed, Jawed
    Falanga, Anna
    Sabbah, Michele
    Garderet, Laurent
    Terpos, Evangelos
    Elalamy, Ismail
    Van Dreden, Patrick
    Dimopoulos, Meletios A.
    HEMATO, 2022, 3 (01): : 188 - 203
  • [2] Prothrombotic Profile in Patients with Active Multiple Myeloma and the Impact of Immunomodulators: The Roadmap-MM Study
    Van Dreden, Patrick
    Papageorgiou, Loula
    Lefkou, Eleftheria
    Fotiou, Despina
    Kastritis, Efstathios
    Terpos, Evangelos
    Rousseau, Aurelie
    Sabbah, Michele
    Grusse, Matthieu
    Mbemba, Elisabeth
    Elalamy, Ismail
    Dimopoulos, Meletios Athanasios
    Gerotziafas, Grigoris
    BLOOD, 2023, 142
  • [3] Derivation of Prediction Model for Treatment Failure Risk in Multiple Myeloma Patients Based on Biomarkers of Hypercoagulability. The Prospective Observational ROADMAP-MM-CAT Study
    Gerotziafas, Grigoris
    Fotiou, Despina
    Sergentanis, Theodoros
    Papageorgiou, Loula
    Rousseau, Aurelie
    Van Dreden, Patrick
    Elalamy, Ismail
    Larsen, Annette
    Falanga, Anna
    Terpos, Evangelos
    Mohty, Mohamad
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S323 - S323
  • [4] Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients.
    Grosbois, B
    Bellissant, E
    Moreau, P
    Attal, M
    Zerbib, R
    BLOOD, 2001, 98 (11) : 163A - 163A
  • [5] Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly diagnosed chemotherapy Naive Patients with Multiple Myeloma at Risk for Cancer-associated Thrombosis. The Observational ROADMAP-CAT-MM Study
    Fotiou, D.
    Papageorgiou, L.
    Salta, S.
    Terpos, E.
    Fareed, J.
    VanDreden, P.
    Lefkou, E.
    Larsen, A. K.
    Elalamy, I.
    Dimopoulos, M. A.
    Gerotziafas, G. T.
    THROMBOSIS RESEARCH, 2018, 164 : S235 - S235
  • [6] In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study
    Gerotziafas, Grigorios T.
    Fotiou, Despina
    Van Dreden, Patrick
    Sergentanis, Theodoros N.
    Elalamy, Ismail
    Papageorgiou, Loula
    Grusse, Matthieu
    Salta, Stella
    Psaltopoulou, Theodora
    Larsen, Annette
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    BLOOD, 2018, 132
  • [7] Clinical presentation, prognostic factors and treatment outcome of multiple myeloma (MM) in African American (AA) patients.
    Badros, Ashraf Z.
    Goloubeva, Olga
    Chumsri, Saranya
    Ruehle, Kathleen
    Ning, Yi
    Meekins, Joann
    Guedez, Liliana
    Rapoport, Aaron P.
    Meisenberg, Barry
    Akpek, Gorgon
    Yanovich, Saul
    Sausville, Edward
    BLOOD, 2006, 108 (11) : 345B - 345B
  • [8] Treatment patterns in patients with multiple myeloma (MM): A retrospective study using Medicare data.
    Lin, Peggy L.
    Latremouille-Viau, Dominick
    Sasane, Medha
    Gagnon-Sanschagrin, Patrick
    Divan, Hozefa A.
    Drea, Edward Joseph
    Guerin, Annie
    Hari, Parameswaran
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] RISK STRATIFICATION WITH PRE-TREATMENT METABOLITE RISK SCORE FOR CARFILZOMIB-RELATED CARDIOTOXICITY IN MULTIPLE MYELOMA PATIENTS.
    Nguyen, T.
    Tantawy, M.
    Zhou, Y.
    Rubinstein, S.
    Garrett, T.
    Baz, R.
    Fradley, M.
    Lu, Q.
    Lenihan, D.
    Cornell, R.
    Gong, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S66 - S66
  • [10] Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.
    Korde, Neha
    Zingone, Adriana
    Kwok, Mary
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Costello, Rene
    Yancey, Mary Ann
    Mulquin, Marcia
    Calvo, Katherine R.
    Maric, Irina
    Tembhare, Prashant
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Arthur, Diane Carol
    Choyke, Peter L.
    Kurdziel, Karen A.
    Steinberg, Seth M.
    Raffeld, Mark
    Roschewski, Mark J.
    Landgren, Ola
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345